NextCure, Inc. 8K

Avere Therapeutics, NextCure, and an Avere stockholder entered into a binding support agreement requiring the stockholder to back NextCure’s planned two-step merger with Avere, restrict share transfers, waive appraisal rights, and terminate certain stockholder rights upon closing.

On July 14, 2026, Avere Therapeutics, Inc. entered into a Company Support Agreement with NextCure, Inc. and a specified Avere stockholder under which the stockholder agrees, in connection with a concurrently executed Agreement and Plan of Merger and Reorganization involving Avere, NextCure and two NextCure merger subsidiaries, to vote all of the stockholder’s Avere shares in favor of the merger and related transactions, not to transfer or encumber those shares except for limited permitted transfers (with similar support obligations binding transferees), to grant an irrevocable proxy to enforce these voting commitments if the stockholder fails to do so, to waive appraisal and similar dissenters’ rights, to refrain from solicitation of alternative transactions, and to terminate certain existing stockholder and investor rights agreements immediately prior to the first merger effective time, with the support agreement itself terminating upon either the first merger effective time, termination of the merger agreement, or mutual written agreement of the parties.

Filing Facts

CIK

1661059

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-083326

Alert Tier

8